血清IL-18对肝细胞癌患者的预后价值  

Serum interleukin-18 as a prognostic factor for hepatocellular carcinoma patients

作　　者：闭肇龙[1] 侯恩存[1] 吴波[1] 颜世能[1] 

机构地区：[1]广西中医药大学附属瑞康医院,广西南宁530011

出　　处：《中国现代医学杂志》2013年第22期34-37,共4页China Journal of Modern Medicine

摘　　要：目的探讨血清IL-18水平与肝细胞癌(HCC)进展的相关性以及对HCC患者预后的价值。方法使用酶联免疫吸附试验(ELISA)检测60例HCC患者的血清IL-18、IL-6和IL-12水平,并以10例健康患者作为对照组。结果 HCC患者的血清IL-18、IL-6和IL-12水平显著高于正常对照组。IL-18水平与HCC静脉侵犯和进展程度显著相关。血清IL-18水平≥105pg/mL与<105pg/mL的患者相比,生存率显著下降。多因素分析表明,血清IL-18水平是HCC患者存活的显著的独立预测指标。结论血清IL-18可以作为HCC侵袭的标志和HCC的独立预后因素之一。[Objective] To determine the relationship of serum interleukin-18 （IL-18） levels with the clinico- pathologic features and prognosis in patients with hepatocellular carcinoma （HCC）. [Method] Serum IL-18, IL-6 and IL-12 levels were measured by enzyme-linked immunosorhent assay （ELISA） from 60 patients with HCC and 10 healthy controls. [Results] Serum IL-18, IL-6 and IL-12 levels of patients with HCC were significantly higher that those of the controls. The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages. Patients with high serum IL-18 levels （≥ 105 pg/mL） had a poorer survival than those with low serum IL-18 levels （〈10s pg/mL）. Multivariate analysis showed that serum IL-18 level was a significant and independent prognostic factor of survival. [ Conclusion] Serum IL-18 may be an useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC.

关 键 词：IL-18 肝细胞癌 检测 预后 

分 类 号：R735.7[医药卫生—肿瘤]